https://todaysveterinarypractice.com/table-of-contents-july-august-2020/
Hepatology

Neutrophilic Cholangitis in Cats: Are You Missing Out on an Easy Diagnosis?

Neutrophilic Cholangitis in Cats: Are You Missing Out on an Easy Diagnosis?
GET A DEFINITIVE DIAGNOSIS Hepatopathies such as cholangitis can be difficult to identify; diagnostics include imaging, cytology, histopathology, and various lab tests. Pixel-Shot/shutterstock.com
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Inflammatory and infectious hepatobiliary diseases are significant causes of morbidity and, less frequently, mortality in cats.1 Inflammatory hepatobiliary disease is the second most common feline hepatic disease in the United States.2 In 2003, the World Small Animal Veterinary Association (WSAVA) standardization committee proposed a histologic classification scheme in an effort to define discrepancies between the published histologic features of lymphocytic portal hepatitis and chronic lymphocytic cholangitis and establish an international diagnostic terminology for hepatopathies.3,4 This scheme differentiated inflammation of the bile ducts (cholangitis) into 4 categories: neutrophilic, lymphocytic, destructive, and chronic (associated with liver fluke infestation).4 This article focuses on acute neutrophilic cholangitis and chronic neutrophilic cholangitis in cats.

Signalment, clinical signs, minimal database, and imaging can help prioritize inflammatory, infectious, and neoplastic hepatopathies and hepatic lipidosis; however, liver or bile cytology and culture or tissue biopsy are essential to reach a definitive diagnosis.

PATHOPHYSIOLOGY AND CLINICAL SIGNS

Neutrophilic cholangitis is more common in cats than in dogs.4 It is subclassified into acute and chronic neutrophilic cholangitis.1 The proposed pathogenesis is secondary to reflux of ascending intestinal bacterial infections.1,5 Histologically, neutrophils are noted within the bile duct lumen, closely associated with the bile duct or between the biliary epithelial cells. If the inflammation extends beyond the limiting plate and into the hepatic parenchyma, the diagnosis is cholangiohepatitis. Progressive disease can result in bile duct rupture with bile leakage, necrosis, and abscesses.4

Prior studies suggested that cats with acute neutrophilic disease were younger and more likely to have a fever, weight loss, and a neutrophilic left shift;3,6,7 however, later research identified overlap in clinical and laboratory findings with acute and chronic disease.1 The most common clinical signs include lethargy, vomiting, weight loss, and decreased appetite. Physical examination abnormalities are not commonly detected but include fever (22% of cases), icterus (34%), and hepatomegaly (21%). Abnormalities on complete blood cell counts are detected in less than half of cats with neutrophilic cholangitis and include leukocytosis (39%), band neutrophils (33%), and anemia (34%). Even in cats with moderate to severe cholangitis, serum liver enzyme activity can be normal.6

LABORATORY SIGNS

Depending on the study, the most consistent abnormality in serum biochemistry panel results is elevation in aspartate transaminase activity (AST; 98% of cats). Variably increased activities of alanine transaminase (ALT; 50% to 57% of cats), alkaline phosphatase (ALP; 14% to 48%), and gamma-glutamyl transferase (GGT) have been noted. The sensitivity of certain serum liver enzymes (ALT, ALP, GGT) appears to be low in cats with cholangitis.6 Many cats are hyperbilirubinemic (66%); however, hepatic synthetic parameters are infrequently abnormal.1,6 Liver function testing using fasting and postprandial serum bile acid concentrations with cutoffs of 15 µmol/L and 20 µmol/L, respectively, had higher specificity than did enzymatic testing and should be considered if hepatic disease is suspected in cats with normal enzyme activities and bilirubin concentration.8

Abnormalities of coagulation parameters, inhibitors of the coagulation system, and fibrinolytic proteins are common in cats with hepatobiliary diseases. Abnormalities include prolongation of prothrombin time (4% to 77% of cases) and partial thromboplastin time (25% to 55%), reduced factor VII (68%) and XIII (31% to 78%, 75% for cats with inflammatory liver disease) activity, and increased PIVKA (protein induced by vitamin K absence; 75%), D-dimer concentrations (83%), and α2-plasmin inhibitor activity (67%).9-11

IMAGING

Hepatobiliary abnormalities are frequently detected during ultrasound examination in cats with neutrophilic cholangitis. They include hyperechoic echogenicity with or without hepatomegaly, bile duct or gallbladder distention, and increased gallbladder sediment (Figures 1 and 2). Other abnormalities frequently noted in cats with neutrophilic cholangitis involve the pancreas (pancreatomegaly, hypoechoic parenchyma, hyperechoic peripancreatic parenchyma) and/or gastrointestinal tract (thickened walls, fluid distention).1 Of note, a retrospective study evaluating multiple hepatobiliary ultrasonographic criteria— including liver parenchymal echogenicity and echotexture, portal venous clarity, gallbladder wall thickness, bile duct diameter, and the character of gallbladder precipitate—was unable to differentiate between a normal liver and diffuse infiltrative liver diseases (hepatic inflammation, cancer, or lipidosis).12 Another retrospective study was also unable to detect statistically significant abnormalities in distinguishing lymphocytic and neutrophilic forms of cholangitis.13 Diagnosis of diffuse liver diseases based on ultrasound findings with or without routine clinical biochemical or hematologic data should be made with caution, even by skilled ultrasonographers.12 Ultrasonography does permit guided percutaneous collection of samples for cytologic or histologic examination.

CYTOLOGY

Fine-needle aspiration (FNA) with cytologic examination has distinct advantages and limitations in evaluating cats with hepatic disorders. It is cost-effective; can be performed expediently and easily, usually without the need for sedation or anesthesia; requires limited preprocedure testing (coagulation is not typically necessary); and provides diagnostic information rapidly compared with liver histopathology.14 Complications are uncommon. With ultrasound guidance, it can be performed with either diffuse or focal disease. Its important limitation is the very small sample size (cells), which does not reflect the morphology of the parenchymal architecture and can fail to correctly identify the primary hepatic disorder.14 In one study evaluating feline hepatopathies, only 51% of cases had an overall agreement between the cytologic and histopathologic diagnoses. Inflammatory disease was correctly diagnosed in 27% of cases.15 This author agrees with others that FNA cytology is a useful diagnostic procedure with many advantages, but a multistep diagnostic approach is preferable, particularly with nonvacuolar diseases16 or equivocal diagnoses, or in cats with a cytologic diagnosis of hepatic lipidosis that does not improve with treatment.

HISTOPATHOLOGY

Histopathology of hepatic disorders describes the distribution of abnormalities in hepatobiliary and vascular structures and may be classified as focal, multifocal, zonal, locally extensive, or diffuse panlobular.17 Cholangitis was initially described as a diffuse process; however, similar to pancreatitis,18 it has since been determined to be either diffuse or limited in distribution (focal, multifocal),4 with varying severity of histopathology between liver lobes in cats.1 These findings support the recommendation to obtain biopsy samples from multiple liver lobes to achieve a complete understanding of disease severity.1

The 3 main hepatic biopsy techniques are ultrasound-guided percutaneous needle biopsy, laparoscopic-assisted biopsy, and wedge biopsy via laparotomy. Each technique has advantages and disadvantages. Needle biopsy is a rapid, cost-effective, minimally invasive method of obtaining liver tissue; however, compared to wedge biopsy, this technique has been shown to result in a one-third reduction in the median surface area of the biopsy specimen. This reduction can result in sampling errors, and important pathologic lesions can be overlooked or misjudged.17 The most common adverse reaction observed with needle biopsy is hemorrhage, which is independent of coagulation testing but is more likely if thrombocytopenia (≤80 × 103/µL platelets) or elevated activated partial thromboplastin time is detected. Less frequently, unintended tissues (e.g., large blood vessels, biliary structures, body wall, digestive tract, pancreas, diaphragm, lung) are sampled and pain is noted.17,19-21 Major complications are recognized within 10 hours21 but are typically evident within 0.5 to 1 hour after the procedure.14

The major advantage of laparoscopic-assisted biopsy and wedge biopsy via laparotomy is the larger size of the tissue sample, which more accurately correlates with the underlying pathology.17 Laparoscopic biopsy forceps typically obtain samples approximately 5 mm in diameter (45 mg of liver tissue); surgical sampling provides for a wider range of sample sizes (ideally at least 1 cm and preferably 2 cm deep).14,22

Bacterial culture (aerobic and anaerobic) is an important component of the diagnostic evaluation of feline hepatobiliary diseases. In one study involving cats with hepatobiliary disease, 36% of bile samples … had positive bacterial growth.23

BACTERIAL CULTURE AND SENSITIVITY TESTING

Bacterial culture (aerobic and anaerobic) is an important component of the diagnostic evaluation of feline hepatobiliary diseases. In one study involving cats with hepatobiliary disease, 36% of bile samples and 14% of liver samples had positive bacterial growth.23 A single bacterial species was detected in 83% of cases.23 Bile samples can be obtained by percutaneous ultrasound-guided cholecystocentesis, laparoscopic-assisted cholecystocentesis, or cholecystocentesis at exploratory coeliotomy (Figure 3).24 Uncommon complications of these procedures include gallbladder rupture and bile peritonitis.3,24 Bile cytology in cats with neutrophilic cholangitis can reveal neutrophilic inflammation. Escherichia coli, either alone or in combination with obligate or facultative anaerobes, is the most commonly reported organism in bile cultures.3 Other reported organisms include Enterobacteriaceae (Salmonella enterica, Klebsiella, Enterobacter) and Streptococcus, Enterococcus, Actinomyces, Acinetobacter, Pasteurella, Clostridia and Bacteroides species.3 Bacteria are isolated by aerobic or anaerobic culture in a few cases of neutrophilic cholangitis/cholangiohepatitis;25 however, newer tests, including fluorescent in situ hybridization, may be more sensitive in detecting bacterial infections.5

Ascending infection with enteric bacteria is the most likely source of hepatobiliary infections; however, hematogenous seeding is possible.3,5 The unique dual entry of the common bile and pancreatic ducts at the major duodenal papilla in the duodenum may lead to the increased risk of reflex of enteric contents and/or pancreatic secretions.3 The association of pancreatitis and cholangitis is theorized to be associated with the shared opening of the pancreatic and common bile ducts in the cat.1

THERAPY

The primary specific therapy for neutrophilic cholangitis/cholangiohepatitis is antibiotics (Table 1),26 ideally directed by bacterial culture and sensitivity testing. Often, antibiotics must be chosen presumptively pending culture results. Antibiotics should be active against aerobic and enteric bacteria and excreted in the bile in an active form. Commonly used antibiotics include ampicillin, amoxicillin–clavulanate potassium, ampicillin–sulbactam, ticarcillin disodium–clavulanate potassium, and metronidazole. Based on their potential side effects, less frequently used antibiotics include chloramphenicol, tetracycline, and erythromycin. Therapy for 2 months has been suggested.25 The optimal duration of treatment has not been determined with prospective trials.

Nonspecific therapies are important since some cats with neutrophilic cholangitis/cholangiohepatitis are critically ill. Treatment for dehydration and correction of electrolyte derangements, coagulopathies, and/or hypotension may be needed. Appetite stimulants may be beneficial for low-grade inappetence; however, with persistent inappetence, placement of an enteral feeding tube (esophagostomy or gastric tube) should be considered. Protein restriction is only required in cats with hepatic encephalopathy; otherwise, a highly digestible, moderate-fat diet is often chosen.27 Hepatic encephalopathy appears to be less common in cats with acquired liver disease; if present, it can be treated with lactulose or oral antibiotics.

Other nonspecific treatments include controlling nausea and/or vomiting, reducing gastric acid, and, less commonly, alleviating pain (more commonly detected with pancreatitis). If complete biliary obstruction is present, and in some cases of choleoliths, surgical intervention is recommended. Previously, biliary-to-intestinal diversion (i.e., cholecystoduodenostomy or cholecystojejunostomy) was recommended in cases of complete extrahepatic bile duct obstruction. Due to high postsurgical morbidity,28 alternative techniques have been proposed, including choledochal stenting;29 however, compared with dogs, cats may have greater morbidity with choledochal stenting.29 Ursodeoxycholic acid is often used for its anti-inflammatory, immunomodulatory, and antifibrotic properties. Ursodeoxycholic acid increases the fluidity of biliary secretions, but the benefits of its use should be weighed against its risks in cats at risk for a biliary obstruction or choleoliths.

Protein restriction is only required in cats with hepatic encephalopathy; otherwise, a highly digestible, moderate-fat diet is often chosen.27

CONCLUSION

The prognosis in cats with acute cholangitis appears good, with median survival times greater than 1 year.3,6 Poor outcomes are most likely related to concurrent diseases6 such as pancreatitis, inflammatory bowel disease, and, to a lesser degree, nephritis.30,31

Adapted from Forman MA. Feline inflammatory/infectious hepatic disease. In: Ettinger SJ, Feldman EC, Côté E, eds. Textbook of Veterinary Internal Medicine.
8th ed. St Louis, MO: Elsevier; 2017.

References

1. Callahan Clark JE, Haddad JL, Brown DC, et al. Feline cholangitis: a necropsy study of 44 cats (1986-2008). J Feline Med Surg 2011;13(8):570-576.

2. Caney SMA, Gruffed-Jones TJ. Feline inflammatory liver disease. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine. 6th ed. Philadelphia, PA: WB Saunders; 2005:1448-1453.

3. Brain PH, Barrs VR, Martin P, et al. Feline cholecystitis and acute neutrophilic cholangitis: clinical findings, bacterial isolates and response to treatment in six cases. J Feline Med Surg
2006;8(2):91-103.

4. Cullen JM. Summary of the World Small Animal Veterinary Association standardization committee guide to classification of liver disease in dogs and cats. Vet Clin North Am Small Anim Pract
2009;39(3):395-418.

5. Twedt DC, Cullen J, McCord K, et al. Evaluation of fluorescence in situ hybridization for the detection of bacteria in feline inflammatory liver disease. J Feline Med Surg 2014;16(2):109-117.

6. Gagne JM, Weiss DJ, Armstrong PJ. Histopathologic evaluation of feline inflammatory liver disease. Vet Pathol 1996;33:521-526.

7. Day DG. Feline cholangiohepatitis complex. Vet Clin North Am Small Anim Pract 1995;25(2):375-385.

8. Center SA, Erb HN, Joseph SA. Measurement of serum bile acids concentrations for diagnosis of hepatobiliary disease in cats. JAVMA 1995;207(8):1048-1054.

9. Dircks B, Nolte I, Mischke R. Haemostatic abnormalities in cats with naturally occurring liver diseases. Vet J 2012;193(1):103-108.

10. Lisciandro SC, Hohenhaus A, Brooks MB. Coagulation abnormalities in 22 cats with naturally occurring liver disease. J Vet Intern Med 1998;12(2):71-75.

11. Center SA, Warner K, Corbett J, et al. Proteins invoked by vitamin K absence and clotting times in clinically ill cats. J Vet Intern Med 2000;14(3):292-297.

12. Feeney DA, Anderson KL, Ziegler LE, et al. Statistical relevance of ultrasonographic criteria in the assessment of diffuse liver disease in dogs and cats. Am J Vet Res 2008;69(2):212-221.

13. Marolf AJ, Leach L, Gibbons DS, et al. Ultrasonographic findings of feline cholangitis. JAAHA 2012;48(1):36-42.

14. Rothuizen J, Twedt DC. Liver biopsy techniques. Vet Clin North Am Small Anim Pract 2009;39(3):469-480.

15. Wang KY, Panciera DL, Al-Rukibat RK, et al. Accuracy of ultrasound-guided fine-needle aspiration of the liver and cytologic findings in dogs and cats: 97 cases (1990-2000). JAVMA 2004;224(1):75-78.

16. Willard MD, Weeks BR, Johnson M. Fine-needle aspirate cytology suggesting hepatic lipidosis in four cats with infiltrative hepatic disease. J Feline Med Surg 1999;1(4):215-220.

17. Cole TL, Center SA, Flood SN, et al. Diagnostic comparison of needle and wedge biopsy specimens of the liver in dogs and cats. JAVMA 2002;220(10):1483-1490.

18. De Cock HE, Forman MA, Farver TB, et al. Prevalence and histopathologic characteristics of pancreatitis in cats. Vet Pathol 2007;44(1):39-49.

19. Proot SJ, Rothuizen J. High complication rate of an automatic Tru-Cut biopsy gun device for liver biopsy in cats. J Vet Intern Med 2006;20(6):1327-1333.

20. Leveille R, Partington BP, Biller DS, et al. Complications after ultrasound-guided biopsy of abdominal structures in dogs and cats: 246 cases (1984-1991). JAVMA 1993;203(3):413-415.

21. Bigge LA, Brown DJ, Penninck DG. Correlation between coagulation profile findings and bleeding complications after ultrasound-guided biopsies: 434 cases (1993-1996). JAAHA 2001;37(3):228-233.

22. Mayhew PD. Advanced laparoscopic procedures (hepatobiliary, endocrine) in dogs and cats. Vet Clin North Am Small Anim Pract 2009;39(5):925-939.

23. Wagner KA, Hartmann FA, Trepanier LA. Bacterial culture results from liver, gallbladder, or bile in 248 dogs and cats evaluated for hepatobiliary disease: 1998-2003. J Vet Intern Med 2007;21(3):417-424.

24. Savary-Bataille KC, Bunch SE, Spaulding KA, et al. Percutaneous ultrasound-guided cholecystocentesis in healthy cats. J Vet Intern Med 2003;17:298-303.

25. Marks SL. Update on the diagnosis and management of feline cholangiohepatitis. Waltham Feline Medicine Symposium. 2003.

26. Plumb DC. Plumb’s Veterinary Drug Handbook [online edition]. 7th ed. Stockholm, WI: PharmaVet Inc; 2012.

27. Center SA. Nutritional support for dogs and cats with hepatobiliary disease. J Nutr 1998;128(12 Suppl):2733S-2746S.

28. Bacon NJ, White RA. Extrahepatic biliary tract surgery in the cat: a case series and review. J Small Anim Pract 2003;44(5):231-235.

29. Mayhew PD, Weisse CW. Treatment of pancreatitis-associated extrahepatic biliary tract obstruction by choledochal stenting in seven cats. J Small Anim Pract 2008;49(3):133-138.

30. Forman MA, Marks SL, De Cock HE, et al. Evaluation of serum feline pancreatic lipase immunoreactivity and helical computed tomography versus conventional testing for the diagnosis of feline pancreatitis.
J Vet Intern Med 2004;18(6):807-815.

31. Weiss DJ, Gagne JM, Armstrong PJ. Relationship between inflammatory hepatic disease and inflammatory bowel disease, pancreatitis, and nephritis in cats. JAVMA 1996;209(6):1114-1116.

DMCA.com Protection Status
[2
[2
2]
2]
MENU